Home » Interviews » INTERVIEW: Why Sativa Investments contract with Kings College London is an important step
Sativa Investments PLC

INTERVIEW: Why Sativa Investments contract with Kings College London is an important step

Sativa Investments plc (NEX: SATI) CEO Geremy Thomas joins DirectorsTalk to discuss its contract with Kings College London. Geremy explains how it fits in with the overall company strategy, the relevance of its 1000th test at PhytoVista, Geremy’s thoughts on being the most traded stock on the NEX exchange and what else is happening across the business.

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted. Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa acquires can either be public or private.

Sativa Investments plc has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company, Veritas Pharma Inc., CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture with Germany’s Lexamed GmbH, and an option on a 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.